News | News By Subject | News by Disease News By Date | Search News

Hypotension News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Flamel Technologies (FLML) Receives FDA Approval Of Akovaz     5/2/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
ISI: Merck & Co. (MRK)’s Zetia News The Rising Tide To Lift All LDL Boats     11/17/2014
Flamel Technologies (FLML) Wins FDA Approval For VAZCULEP     6/30/2014
Chelsea Therapeutics, Inc. (CHTP) Pops As FDA Finally Approves NORTHERA™     2/19/2014
Will the FDA Approve Chelsea Therapeutics, Inc. (CHTP)'s Northera?     3/28/2012
Novartis Corporation (NVS) Gets FDA OK For Tekamlo, a Blood Pressure Treatment     8/30/2010
Actelion Ltd. (ALIOF.PK)'s REVEAL(R) Study May Advance Patient Care in Pulmonary Arterial Hypertension     5/19/2010
Chelsea Therapeutics, Inc. (CHTP) Release: Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension in Phase III Trials; Stock Rises 23.11% at 1:29pm ET     10/2/2009
FDA Approves Novartis Pharmaceuticals Corporation (NVS)'s (JOBS) Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill     5/1/2009
Pfizer Inc. (PFE) Shares Slipped Tuesday On Data That Show Experimental Cholesterol Drug Raises Blood Pressure     11/1/2006

News from Around the Web

Press Releases
Martindale Pharma Launches First Ready-To-Use Presentation Of Phenylephrine     4/12/2016
La Jolla Pharma (LJPC) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress     8/7/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase III Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension     3/24/2015
La Jolla Pharmaceutical Company (LJPC) Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension     2/9/2015
Chelsea Therapeutics, Inc. (CHTP) Announces First Patient Dosed In NORTHERA™ (Droxidopa) Study 401 For The Treatment Of Symptomatic NOH     12/9/2013
Chelsea Therapeutics, Inc. (CHTP) Announces FDA Advisory Committee to Review NORTHERA™ (droxidopa)     10/10/2013
Chelsea Therapeutics, Inc. (CHTP) Resubmits New Drug Application for NORTHERA™ (droxidopa) for the Treatment of Symptomatic NOH     7/9/2013
Chelsea Therapeutics, Inc. (CHTP) Release: Combined Northera™ (droxidopa) Data From Two Phase 3 Trials Confirm Symptom Improvement in Patients With Neurogenic OH     6/21/2012
Chelsea Therapeutics, Inc. (CHTP) Completes End-of-Review Meeting With FDA for Northera(TM) (droxidopa) Capsules New Drug Application     5/22/2012
Chelsea Therapeutics, Inc. (CHTP) Announces FDA Advisory Committee Meeting Date for Review of NORTHERA(TM) NDA for the Treatment of Symptomatic NOH     1/3/2012
Chelsea Therapeutics, Inc. (CHTP) Submits New Drug Application for NORTHERA(TM) (droxidopa) for the Treatment of Symptomatic NOH     9/28/2011
Chelsea Therapeutics, Inc. (CHTP) Announces New Data from Northera Phase III Program in Neurogenic Orthostatic Hypotension Presented at MDS 15th International Congress of Parkinson's Disease and Movement Disorders     6/10/2011
Chelsea Therapeutics, Inc. (CHTP) Confirms Plan to File Northera NDA for the Treatment of Neurogenic Orthostatic Hypotension in Third Quarter 2011 and Intent to Pursue Supplemental Falls Claim Following Approval     4/18/2011
Chelsea Therapeutics, Inc. (CHTP) Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated With Neurogenic Orthostatic Hypotension     2/2/2011
Chelsea Therapeutics, Inc. (CHTP) Reports Data Demonstrating Sustained Symptomatic Benefit of Northera in Neurogenic Orthostatic Hypotension Over 12-Month Treatment Period     1/20/2011

//-->